🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi
Joined June 2022
- Tweets621
- Following1.8K
- Followers4.6K
- Likes1.8K
Pinned Tweet
🤔 Heading to #ASH26?
⭐️ Join us for a complimentary in-person Hematology Board Review for fellows & anyone prepping for boards 🩸
📅 Friday, December 11, 2026
🕗 8:00 AM–12:00 PM CT
📍 420 Julia St., New Orleans, LA
🔗 Register: bit.ly/hemeboards
🤖 Made with AI
TwoOncDocs retweeted
Excited to join the Clinicals to Exam – Oncology Board Review during #ASH2026 in New Orleans on December 11!
Looking forward to strengthening my clinical knowledge, gaining valuable insights, and connecting with fellow hematology/oncology professionals!
#HemeOnc #Oncology #MedEd @OncUpdates @OncBrothers @TwoOncDocs #hematology
OncologyBrothers.regfox.com/…
We are back this week with our final #breastcancer series on metastatic breast cancer 🩷
A 62yo F presents with newly diagnosed ER-positive, HER2-negative metastatic breast cancer with asymptomatic bone and nodal disease.
Which of the following is a preferred tx?
4%Letrozole alone
2%Paclitaxel
92%Aromatase inh+ ribociclib
2%Fulvestrant
53 votes • Final results TwoOncDocs retweeted
🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review!
👀 Here is a sneak peek of your board review day!
🗓️ In-person w/@OncBrothers + @TwoOncDocs
🔗 Register: bit.ly/hemeboards
#OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow
TwoOncDocs retweeted
🤔Headed to #ASH26? Join for a FREE board review!
🗓️ In-person w/@OncBrothers + @TwoOncDocs
📅 Friday, Dec 11th
📍 Common House,New Orleans
🔗 Register: bit.ly/hemeboards
#OncTwitter #HemOnc #MedX #MedTwitter #ASH #MedEd @HemOncFellows @hemeoncfellow @ASH_hematology
TwoOncDocs retweeted
Highly recommended! 💕 2026 update focusing on metastatic breast cancer @TwoOncDocs There is no better way to learn new Oncology meds other than treat them like new songs (listen frequently) 🎶 Learn from the BEST on proper pronunciations of Onc meds. podcasts.apple.com/us/podcas…
Today part 2 of our breast cancer series is out on Localized #BreastCancer 🩷
A 39yo woman with pt1c (1.5cm) ER+ breast cancer undergoes a lumpectomy with SLNB.
Which of the following adjuvant endocrine therapies is preferred in PRE menopausal women?
0%Anastrozole alone
4%Letrozole alone
96%Tamoxifen +/- OFS
0%Fulvestrant alone
26 votes • Final resultsWe are back with 2026 Breast Cancer updates! 🩷
In today’s episode, we cover an introduction on breast cancer, screening, prevention, DCIS, LCIS & more.
At what age range, should patients with triple negative breast cancer have genetic testing?
35%30-45yo
0%45-60yo
0%60+yo
65%All patients with TNBC
26 votes • Final results TwoOncDocs retweeted
Today 9/24/26 new approval in 2L clear cell mRCC with some caveats #LITESPARK011
💢 4mo PFS gain, higher ORR (53% vs 40%) & DOR (23 v 12mo)
💢 OS is not yet significant
💢 how does it perform post 1L IO/IO vs IO/TKI, weight of extra toxicity & optimal sequencing still unclear
Based off LITESPARK-011: Belzutifan + Lenvatinib is now @FDA ✅ in 2L RCC after IO exposure:
PhIII: Bel + Len vs. Cabo
- mPFS 14.6mos vs. 10.7mos (HR: 0.74)
- mOS 33.7mos vs. 28.6mos (HR: 0.85, p=0.061).
- AEs: 72% vs. 66% w/ Gr ≥ 3
#OncTwitter #gusm @OncUpdates
TwoOncDocs retweeted
Highly recommended: @TwoOncDocs Yes for Pharmacy students as well
Localized NSCLC in 2026: new staging, expanded perioperative options, and a driver-directed pathway that reshapes management. The Two Onc Docs deliver the high-yield takeaways, tune in now!
🎙️Full episode: hubs.li/Q04xhhFv0
So exciting to see the FDA approval for this today ‼️‼️
Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹
#RASolute today presented at #ASCO26:
Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo)
A HUGE advance in one of the most lethal cancers 💜
New episode out today updating Iron Overload Syndromes! 🩸
A 52M is found to have an elevated ferritin and a transferrin saturation of 60%. Genetic testing confirms C282Y homozygosity.
Which is the most appropriate 1L treatment?
@HemOncFellows #hematology #boardreview
14%Deferasirox
83%Therapeutic phlebotomy
3%Deferoxamine
0%Liver transplantation
35 votes • Final results TwoOncDocs retweeted
Great work
Well worth listening to
@OpenMedicineHQ
Burnout is extremely prevalent in medicine & specifically in oncology
- in this week’s episode we discuss Wellness in Oncology tips w/ @doclauravater & the SMILE Scale - a wellness behavioral tool designed to measure and encourage healthy habits ❤️🩹
podcasts.apple.com/us/podcas…
TwoOncDocs retweeted
We love ourselves a @thefellowoncall x @TwoOncDocs! Thank you @wimedicineorg #COSMO2026 for inviting us to present our workshop “Build, Connect, Rise: Education, Mentorship and Career Development in the Digital Age of Oncology”! – at Chicago, IL
RT @DrKarineTawagi: 📣 FDA approval of Pluvicto triplet vs ADT/ARPI for mCSPC (APMS) vs ADT/ARPI #PSMAddition
✔️ rPFS: HR 0.72
✔️ time to m…
TwoOncDocs retweeted
🎙️ New episode alert: Samantha A. Armstrong, MD, and Karine Tawagi, MD break down DLBCL presentation on Two Onc Docs, from classic B symptoms to the 30-40% of cases with GI, CNS, or thyroid involvement, and why excisional biopsy is required. 🔬
Access the full OncLive® episode: hubs.li/Q04qyRzH0
@TwoOncDocs @SamArmstrongMD @DrKarineTawagi #DLBCL #Lymphoma #HemOnc